Occurrence of Selected Generic Drugs 5

Project Title Occurrence of Selected Generic Drugs 5
Date Posted
Thursday, December 13, 2012
Project ID
MSY2_STR61-62
Status
Complete
Deliverables
Description

Summary table assessment of the use of Alosetron hydrochloride (HCL), Ambrisentan, Bosentan, Buprenorphine HCL, Buprenorphine HCL /Nalonxone HCL, Eltrombopag Olamine, Fentanyl, Hydromorphone HCL, Isotretinoin, Lenalidomide, Mifepristone, Oxycodone HCL, Romiplostim, Rosiglitazone Maleate, Rosiglitazone/Glimepiride, Rosiglitazone/Metformin HCL, Thalidomide, and Vigabatrin. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table. Summary tables are precompiled stratified counts. Queries were executed in August 2011. This report includes data from 15 Data Partners.

This document is an Excel spreadsheet that includes multiple layers of data configured using pivot tables. If you do not have Excel, click here to obtain a free version of Microsoft’s Excel Viewer.

If you are using a web page screen reader and are un/able to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
alosetron HCL
ambrisentan
bosentan
buprenorphine HCL
eltrombopag olamine
fentanyl
hydromorphone HCL
isotretinoin
lenalidomide
mifepristone
oxycodone HCL
romiplostim
rosiglitazone maleate
rosiglitazone/glimepiride
rosiglitazone/metformin HCL
thalidomide
vigabatrin
Time Period
2001 - 2010
Assessment Type
Exploratory Analyses
Study Type
Summary Table
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
CDER